Effect of protein binding on the activity of voriconazole alone or combined with anidulafungin against aspergillus spp. Using a time-kill methodology;Efecto de la unión a proteínas en la actividad de voriconazol solo o combinado con anidulafungina frente aspergillus spp. Mediante curves de letalidad

Revista Espanola de Quimioterapia

Volumn 25, Issue 1, 2012, Pages 47-55

  Cafini, Fabio ^a   Sevillano, David ^a   Alou, Luis ^a   Gómez Aguado, Fernando ^b   Corcuera, María Teresa ^b   González, Natalia ^a   Guinea, Jesús ^a,c,d   Prieto, José ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Albumin; Anidulafungin; Serum; Time kill; Voriconazole

Indexed keywords

ALBUMIN; ANIDULAFUNGIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; COLORIMETRY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; FUNGAL METABOLISM; FUNGAL STRAIN; HUMAN; MICROSCOPY; MYCELIAL GROWTH; NONHUMAN; PROTEIN BINDING; SERUM;

ANTIFUNGAL AGENTS; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; COLORIMETRY; CULTURE MEDIA; DRUG COMBINATIONS; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; PROTEIN BINDING; PYRIMIDINES; SERUM ALBUMIN; TETRAZOLIUM SALTS; TIME FACTORS; TRIAZOLES;

EID: 84859634534     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Denning, DW. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J Antimicrob Chemother 1991; 28 Suppl. B: 1-16.
2. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360.
3. Barberán J, Mensa J, Fariñas C et al. Recommendations of antifungal treatment in patients with low grade immunosuppression. Rev Esp Quimioter 2008; 21: 127-42.
4. Dockrell DH. Salvage therapy for invasive aspergillosis. J Antimicrob Chemother 2008;61 Suppl 1: i41-i44.
5. Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006; 43: 215-222.
6. Philip A, Odabasi Z, Rodriquez J et al. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005; 49: 3572-3574
7. Petraitis V, Petraitiene R, Hope WW et al. Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlation of the Concentration and Dose Dependent Interaction between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis. Antimicrob Agents Chemother 2009; 53: 2382-2391.
8. Perkhofer S, Jost D, Dierich MP et al. Susceptibility testing of an- idulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. Antimicrob Agents Chemother 2008; 52: 1873-1875
9. van de Sande WW, Mathot RA, Ten Kate MT et al. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Antimicrob Agents Chemother 2009; 53: 2005-2013.
10. Paderu P, Garcia-Effron G, Balashov S et al. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 2007; 51: 2253-2256.
11. Rodrigues AG, Araujo R, Pina-Vaz C. Human albumin promotes germination, hyphal growth and antifungal resistance by Aspergillus fumigatus. Med Mycol 2005; 43: 711-7.
12. Wiederhold NP, Najvar LK, Bocanegra R et al. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother 2007; 51: 1616-20.
13. Odabasi Z, Paetznick V, Rex JH, et al. Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob Agents Chemother 2007;51: 4214-4216
14. Moellering RC, Eliopoulos GM. Principles of anti-infective therapy. In: Mandell, Douglas, and Bennett Principles and Practice of Infectious Diseases-Mandell GL, Bennett JE, Dolin R, eds. Philadelphia: Elsevier Churchill Livingstone, 2005: 242-253.
15. Cafini F, Aguilar L, González N et al. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives. J Antimicrob Chemother 2007; 59: 1185-1189.
16. Sevillano D, Giménez MJ, Alou L et al. Effects of human albumin and serum on the in vitro bactericidal activity of cefditoren against penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2007; 60: 156-158.
17. EUCAST Definitive Document E.DEF 9.1. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds 2008.
18. Antachopoulos C, Meletiadis J, Sein T et al. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob Agents Chemother 2008; 52: 321-328.
19. Kuhn DM, Balkis M, Chandra J et al. Uses and limitations of the XTT assay in studies of Candida growth and metabolism. J Clin Microbiol 2003; 41: 506-508.
20. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45: 649-663.
21. Krishnan S, Manavathu EK, Chandrasekar H. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus. J Antimicrob Chemother 2005; 55:914-920.
22. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998; 42: 3018-3021.
23. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003 Oct;47(10):3165-3169.
24. Pfaller MA. Anidulafungin: an echinocandin antifungal. Expert Opin Investig Drugs. 2004 Sep;13(9):1183-1197.
25. Ishikawa J, Maeda T, Matsumura I et al. Antifungal activity of micafungin in serum. Antimicrob Agents Chemother 2009; 53: 4559-4562.
26. Gifford AH, Klippenstein JR, Moore MM. Serum stimulates growth of and proteinase secretion by Aspergillus fumigatus. Infect Immun 2002; 70:19-26